For Immediate Release
Chicago, IL - July 18, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Valeant Pharmaceuticals International, Inc. (NYSE: VRX - Free Report ), Flexion Therapeutics, Inc. (NASDAQ: FLXN - Free Report ), Ignyta, Inc. (NASDAQ: RXDX - Free Report ) and Anika Therapeutics, Inc. (NASDAQ: ANIK - Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Monday's Analyst Blog:
4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings
Earnings season for the biotech and pharma sector kicks off this week with industry bellwether Johnson & Johnson reporting second quarter results tomorrow before the market opens. Swiss pharma giant Novartis, which was in the news recently related to a favorable FDA advisory panel recommendation for its CAR-T cell therapy, will also be reporting second quarter results tomorrow.
As of Jul 14, 2017, about 30 S&P 500 members or 9.3% of the index's total market capitalization have reported results. A look at our Earnings Preview article shows that total earnings for these companies are up 13.8% from the year-ago quarter while revenues are up 6%.
As far as the Medical sector is concerned, revenues are expected to increase 3.7% though earnings are expected to decline 1%. This is in contrast to the first quarter when earnings rose 5.6% on revenue growth of 5.7%.
While overall sentiment towards pharma and biotech stocks has improved significantly in 2017 with investors focusing more on fundamentals than on issues like drug pricing, it would make sense to avoid drug companies that are sell ranked stocks and do not look well-positioned ahead of 2Q earnings. We have zeroed in on 4 stocks that have a Sell rank -- Zacks Rank #4 (Sell) or #5 (Strong Sell) and have a negative Earnings ESP
for the second quarter. Valeant Pharmaceuticals International, Inc.
(NYSE: VRX - Free Report
Canada-based specialty pharma company, Valeant, has been in the headlines mainly due to the drug pricing controversy and its relationship with Philidor. The Zacks Rank #5 stock, which missed earnings expectations in two of the last four quarters and revenue expectations in the first quarter of 2017, has a negative earnings ESP of 9.38% for the second quarter of 2017. The company, which has been working on simplifying its operating model and reducing debt, will be reporting results on Aug 8. Earnings estimates for 2017 are down 0.5% over the last 30 days. Flexion Therapeutics, Inc.
(NASDAQ: FLXN - Free Report
): Burlington, MA-based Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis. The Zacks Rank #4 stock, which missed loss estimates in two of the last four quarters, has a negative earnings ESP of 7.5% for the second quarter of 2017. Loss estimates for the June quarter and 2017 are up 1.3% and 0.6%, respectively, over the last 7 days. Flexion is expected to report second quarter results on Aug 2.
Ignyta, Inc. (NASDAQ: RXDX - Free Report ): San Diego, CA-based Ignyta is focused on precision medicine in oncology. The Zacks Rank #4 stock, which posted a wider-than-expected loss in two of the last three quarters, has a negative earnings ESP of 13.12% for the second quarter of 2017. Loss estimates for the June quarter and 2017 are up 17.3% and 1.9%, respectively, over the last 30 days. Ignyta is expected to report second quarter results on Aug 8.
Anika Therapeutics, Inc. (NASDAQ: ANIK - Free Report ): Bedford, MA-based Anika is a global, integrated orthopedic medicines company. The Zacks Rank #5 stock, which missed first quarter earnings estimates, has a negative earnings ESP of 4.55% for the second quarter of 2017. While earnings estimates for the June quarter are down 10.2% over the last 30 days, full year 2017 estimates are down 5.6% during this period. Anika will be reporting second quarter results on Jul 26. Year-to-date, the company's shares are down 5.8%, underperforming the Zacks-categorized Medical-Biomedical/Genetics industry which is up almost 9%.
While you can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter , you can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on VRX - FREE
Get the full Report on FLXN - FREE
Get the full Report on RXDX - FREE
Get the full Report on ANIK - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report Flexion Therapeutics, Inc. (FLXN): Free Stock Analysis Report Ignyta, Inc. (RXDX): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research